Pfizer vaccine very effective against Delta variant in adolescents in Israel: study
(VOVWORLD) - The Pfizer/BioNTech COVID-19 vaccine is highly effective at preventing infection and symptomatic disease from the Delta variant among 12- to 18-year-olds, research conducted in Israel shows.
 A vial of the Pfizer vaccine against the coronavirus disease (COVID-19) is seen as medical staff are vaccinated at Sheba Medical Center in Ramat Gan, Israel December 19, 2020. (Photo: REUTERS) |
The findings, published in the New England Journal of Medicine, will likely provide further reassurance the shot is effective against the variant among younger people as the US drug watchdog considers authorising use of the vaccine on children as young as five.
The study found the estimated vaccine effectiveness against documented COVID-19 infection in adolescents was 90%, and 93% against symptomatic COVID-19, on days seven to 21 after the second dose.
Israel's Clalit health maintenance organisation and Harvard University researchers reviewed data from 94,354 vaccine recipients aged 12 to 18 who were matched with an identical number of unvaccinated adolescents from the same age group.